About MDD

Major Depressive Disorder (MDD) is a leading cause of disability in the United States. Affecting millions of people, this highly serious and life threatening condition has a massive personal and economic impact. People suffering from MDD experience debilitating depression, isolation, loss of interest in activities, and extreme feelings of worthlessness. MDD’s long lasting symptoms can lead to an inability to perform routine tasks, missed work, and are a significant risk factor for heart disease and suicide.

Despite the negative personal, social and economic impact of MDD, there is still a critical unmet medical need for people with MDD. SSRIs and SNRIs currently represent the first-line of treatment for depression in the United States. However, up to two-thirds of patients with Major Depressive Disorder do not get an adequate response with single first-line treatment. As many as an additional third become treatment resistant.

Often, additional therapies are included due to the poor response of first-line therapy. These may include: additional antidepressants, mood stabilizers, psychotherapy, phototherapy, or other alternate therapies. However, the numerous side effects and lack of rapid response often lead patients to discontinue therapy.

Because of the challenges in treating MDD, this study is evaluating an investigational drug that may help in the treatment of Major Depressive Disorder.

Explore an investigational drug that may help in the treatment of Major Depressive Disorder.

CONTACT INFORMATION

Millions of people in the United States suffer from Major Depressive Disorder (MDD) but the majority of them aren’t getting the help they need from their first-line treatment.

A clinical research study is currently evaluating an investigational drug for its safety and effectiveness as an antidepressant therapy for Major Depressive Disorder.

LET’S TALK, CONTACT US TO LEARN MORE.
About the Program

PIVOTAL STUDY
All eligible patients will receive the investigational drug or placebo for 3 weeks

MAINTENANCE STUDY
All eligible patients will receive the investigational drug or placebo for up to 2 years

LONG-TERM STUDY
All eligible patients will receive the investigational drug for up to 1 year

This drug will be given to you by injection into a vein in your arm. The placebo looks like the study drug, but has no active drug in it. Neither you nor the person administering the drug will know if you are receiving the active drug or placebo. Patients will continue taking their current prescribed treatment while in these studies.

Why should I participate?

The knowledge gained from this study may help others with Major Depressive Disorder in the future.

The investigational drug being studied may or may not help in the treatment of your depression, and the clinical research team will discuss all potential study benefits and risks with you and answer any questions you may have.

Eligible participants will receive study related tests and procedures at no cost.

How to Participate

If you are interested in participating, you will go through a series of screening assessments including:

- physical exam
- a review of your health and medication history
- blood and urine testing
- ECG (electrocardiogram)

You will also be requested to fast (apart from water) for 8-10 hours and complete a “washout” period of time where you stop taking some or all medications prior to taking the study drug.

If you are eligible and choose to participate, you will be randomly assigned (like a flip of a coin) to receive the investigational drug or a placebo.

Am I Eligible?

You may be eligible to participate in this clinical study if you are:

- 18 – 65 years old
- Diagnosed with Major Depressive Disorder
- Not getting adequate response with your current treatment
- Not pregnant and are willing to use contraceptives to prevent pregnancy during the study

Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you. A clinical research team member will help determine if you meet all necessary criteria to participate.